Plain-English translation of NCT07213297 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study—meaning researchers will monitor and learn from you rather than test a new drug. If you have been diagnosed with hereditary transthyretin amyloidosis (a genetic condition where abnormal proteins build up in your heart, nerves, and other organs), this study will carefully track your health over time. The goal is to understand how this disease affects different people differently and what early warning signs doctors should watch for.
Hereditary transthyretin amyloidosis is a rare, serious disease that affects multiple organs and can progress differently in each patient. Doctors don't yet fully understand what determines when symptoms will start or how quickly the disease will advance. This study aims to fill that gap by gathering detailed medical information from patients like you to help future patients receive earlier diagnosis and better care.
You likely qualify if…
You likely don't qualify if…
You will visit Néstor Kirchner Hospital for thorough medical evaluations, including genetic testing, physical examinations, and various diagnostic tests to assess your heart, nerves, and organ function. The study will follow your health over time to track any changes or disease progression. You may also be asked to share medical records and results from tests you've already had done.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Argentina